These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31806013)

  • 1. Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.
    Al-Ali R; Bauer K; Park JW; Al Abdulla R; Fermi V; von Deimling A; Herold-Mende C; Mallm JP; Herrmann C; Wick W; Turcan Ş
    Acta Neuropathol Commun; 2019 Dec; 7(1):201. PubMed ID: 31806013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
    Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
    Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
    Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
    Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
    Aoki K; Suzuki H; Yamamoto T; Yamamoto KN; Maeda S; Okuno Y; Ranjit M; Motomura K; Ohka F; Tanahashi K; Hirano M; Nishikawa T; Shimizu H; Kitano Y; Yamaguchi J; Yamazaki S; Nakamura H; Takahashi M; Narita Y; Nakada M; Deguchi S; Mizoguchi M; Momii Y; Muragaki Y; Abe T; Akimoto J; Wakabayashi T; Saito R; Ogawa S; Haeno H; Natsume A
    Cancer Res; 2021 Sep; 81(18):4861-4873. PubMed ID: 34333454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
    Aliotta E; Batchala PP; Schiff D; Lopes BM; Druzgal JT; Mukherjee S; Patel SH
    J Neurooncol; 2019 Nov; 145(2):257-263. PubMed ID: 31531788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign.
    Aliotta E; Dutta SW; Feng X; Tustison NJ; Batchala PP; Schiff D; Lopes MB; Jain R; Druzgal TJ; Mukherjee S; Patel SH
    J Neurooncol; 2020 Sep; 149(2):325-335. PubMed ID: 32909115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
    Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
    J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
    Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
    Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas.
    Pei D; Guan F; Hong X; Liu Z; Wang W; Qiu Y; Duan W; Wang M; Sun C; Wang W; Wang X; Guo Y; Wang Z; Liu Z; Xing A; Guo Z; Luo L; Liu X; Cheng J; Zhang B; Zhang Z; Yan J
    Eur Radiol; 2023 May; 33(5):3455-3466. PubMed ID: 36853347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
    Liu Z; Zhang T; Jiang H; Xu W; Zhang J
    Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of
    Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
    AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
    Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of
    Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK
    AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.